Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.65 |
| ▸ | RXRA | P19793 | 8/20 | 0.65 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500378 | 0.88 | NR1H2 (0.52) | NR1H2RXRANR1H3ALOX5 | |
| SCHEMBL3995720 | 0.86 | TSHR (0.50) | NR1H2RXRANR1H3FFAR1FFAR4 | |
| SCHEMBL2552269 | 0.83 | FOLH1 (0.53) | FFAR1FFAR4ALOX5AKR1B1 | |
| Methane SCHEMBL10567951 | 0.81 | FOLH1 (0.52) | FFAR1FFAR4ALOX5AKR1B1 | |
| SCHEMBL5984166 | 0.81 | BCAT2 (0.49) | NR1H2RXRANR1H3AKR1B1 | |
| SCHEMBL1678558 | 0.79 | RXRA (1.00) | NR1H2RXRANR1H3FFAR1FFAR4 | |
| SCHEMBL6237724 | 0.77 | MAOB (0.64) | FFAR1FFAR4ALOX5 | |
| SCHEMBL3498170 | 0.77 | MRGPRX4 (0.55) | NR1H2RXRANR1H3 | |
| SCHEMBL28141293 | 0.76 | AKR1B1 (0.58) | FFAR1FFAR4ALOX5AKR1B1 | |
| SCHEMBL2801838 | 0.75 | ALDH1A1 (0.52) | RXRAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | NR1H2 75/4885RXRA 275/4885NR1H3 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.